1. Medtech Insight
  2. >>Business

Cardio Catch-Up: Trial Of Abbott’s Volt PFA Begins; IDE Study To Start This Year

 
• By Reed Miller

Abbott is behind rivals Boston Scientific and Medtronic in the race to capture share of the emerging pulsed field ablation market. PFA is set to eventually become the most common cardiac ablation modality because it is safer than radiofrequency or cryoablation.

Abbott Volt PFA
Abbott Volt PFA • Source: Abbott

The first 30 atrial fibrillation ablation procedures with Abbott’s Volt PFA (pulsed field ablation) system have been completed in Australia and Europe as part of a clinical trial to support a CE mark.

The company expects the US Food and Drug Administration to approve its plan for a US clinical trial of Volt...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Waters’ Merger With BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs, Analysts Say

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

More from Medtech Insight

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By Marion Webb

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By Elizabeth Orr

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.